WHAT IS CLAIMED IS:

1. A compound of formula I or formula II:



I



II

wherein:

X is O, N, S, SO_2 or C;

Y is selected from: -O-, -NR^{12}-, -S-, -SO-, -SO_2-, and –$CR^{12}R^{12}$-, -NSO_2R^{14}-, -$NCOR^{13}$-, -$CR^{12}COR^{11}$-, -$CR^{12}OCOR^{13}$- and -CO-;

R^{11} is selected from: hydroxy, hydrogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, benzyl, phenyl and C_{3-6}cycloalkyl, where said alkyl, phenyl, benzyl and cycloalkyl groups are unsubstituted or substituted with 1-3 substituents, and where said substituents are independently selected from: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy, -CO_2H, -CO_2-C_{1-6}alkyl and trifluoromethyl;

R^{12} is selected from: hydrogen, C_{1-6} alkyl, benzyl, phenyl and C_{3-6}cycloalkyl, where said alkyl, phenyl, benzyl and cycloalkyl groups are unsubstituted or substituted with 1-3 substituents, and where said substituents are independently selected from: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy, $-CO_2H$, $-CO_2-C_{1-6}$alkyl, and trifluoromethyl;

R^{13} is selected from: hydrogen, C_{1-6}alkyl, $-O-C_{1-6}$alkyl, benzyl, phenyl and C_{3-6}cycloalkyl, where said alkyl, phenyl, benzyl and cycloalkyl groups are unsubstituted or substituted with 1-3 substituents, and where said substituents are independently selected from: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy, $-CO_2H$, $-CO_2-C_{1-6}$alkyl and trifluoromethyl;

R^{14} is selected from: hydroxy, C_{1-6} alkyl, $-O-C_{1-6}$alkyl, benzyl, phenyl, C_{3-6}cycloalkyl, where said alkyl, phenyl, benzyl and cycloalkyl groups are unsubstituted or substituted with 1-3 substituents, and where said substituents are independently selected from: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy, $-CO_2H$, $-CO_2-C_{1-6}$ alkyl and trifluoromethyl;

each Z is independently selected from C or N, where at most two of the Z are N;

R^1 is selected from:

(a) hydrogen,
(b) $-C_{1-6}$alkyl,
(c) $-C_{0-6}$alkyl-O-C_{1-6}alkyl,
(d) $-C_{0-6}$alkyl-S-C_{1-6}alkyl,
(e) $-(C_{0-6}$alkyl)-(C_{3-7}cycloalkyl)-(C_{0-6}alkyl),
(f) hydroxy,
(g) heterocycle,
(h) -CN,
(i) $-NR^{12}R^{12}$,
(j) $-NR^{12}COR^{13}$,
(k) $-NR^{12}SO_2R^{14}$,
(l) $-COR^{11}$,
(m) $-CONR^{12}R^{12}$, and
(n) phenyl;

where said alkyl and cycloalkyl are unsubstituted or substituted with 1-7 substituents, and where said substituents are independently selected from: halo, hydroxy, $-O-C_{1-3}$alkyl, trifluoromethyl, C_{1-3}alkyl, $-O-C_{1-3}$alkyl, $-COR^{11}$, $-SO_2R^{14}$, $-NHCOCH_3$, $-NHSO_2CH_3$, -heterocycle, =O, -CN, and

where said phenyl and heterocycle are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -COR^{11}, C$_{1-3}$alkyl, C$_{1-3}$alkoxy and trifluoromethyl;

R^2 is selected from:

(a) hydrogen,
(b) C$_{1-3}$alkyl, optionally substituted with 1-3 fluoro,
(c) -O-C$_{1-3}$alkyl, optionally substituted with 1-3 fluoro,
(d) hydroxy,
(e) chloro,
(f) fluoro,
(g) bromo,
(h) phenyl,
(i) heterocycle, and
(j) nothing or O (when the Z bonded to R^2 is N);

R^3 is selected from:

(a) hydrogen,
(b) C$_{1-3}$alkyl, optionally substituted with 1-3 fluoro,
(c) -O-C$_{1-3}$alkyl, optionally substituted with 1-3 fluoro,
(d) hydroxy,
(e) chloro,
(f) fluoro,
(g) bromo,
(h) phenyl,
(i) heterocycle, and
(j) nothing or O (when the Z bonded to R^3 is N);

R^4 is selected from:

(a) hydrogen,
(b) C$_{1-3}$alkyl, optionally substituted with 1-3 fluoro,
(c) -O-C$_{1-3}$alkyl, optionally substituted with 1-3 fluoro,
(d) hydroxy,
(e) chloro,
(f) fluoro,
(g) bromo,
(h) phenyl,
(i) heterocycle, and
(j) nothing or O (when the Z bonded to R^4 is N);

R^5 is selected from:

(a) C_{1-6}alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro and optionally substituted with hydroxyl,
(b) -O-C_{1-6}alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,
(c) -CO-C_{1-6}alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,
(d) -S-C_{1-6}alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,
(e) -pyridyl, which is unsubstituted or substituted with one or more substituents selected from: halo, trifluoromethyl, C_{1-4}alkyl, and COR^{11},
(f) fluoro,
(g) chloro,
(h) bromo,
(i) -C_{4-6}cycloalkyl,
(j) -O-C_{4-6}cycloalkyl,
(k) phenyl, which is unsubstituted or substituted with one or more substituents selected from: halo, trifluoromethyl, C_{1-4}alkyl, and COR^{11},
(l) -O-phenyl, which is unsubstituted or substituted with one or more substituents selected from: halo, trifluoromethyl, C_{1-4}alkyl, and COR^{11},
(m) -C_{3-6}cycloalkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,
(n) -O-C_{3-6}cycloalkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,
(o) -heterocycle,
(p) -CN, and
(q) $-COR^{11}$;

R^6 is selected from:

(a) hydrogen,
(b) C_{1-3}alkyl, optionally substituted with 1-3 fluoro,
(c) -O-C_{1-3}alkyl, optionally substituted with 1-3 fluoro,
(d) hydroxy,
(e) chloro,
(f) fluoro,
(g) bromo,

(h) phenyl,
(g) heterocycle, and
(h) nothing, when the Z bonded to R^6 is N;

R^7 is selected from:
(a) hydrogen,
(b) (C_{0-6}alkyl)-phenyl,
(c) (C_{0-6}alkyl)-heterocycle,
(d) (C_{0-6}alkyl)-C_{3-7}cycloalkyl ,
(e) (C_{0-6}alkyl)-COR^{11},
(f) (C_{0-6}alkyl)-(alkene)-COR^{11},
(g) (C_{0-6}alkyl)-SO_3H,
(h) (C_{0-6}alkyl)-W-C_{0-4}alkyl,
(i) (C_{0-6}alkyl)-$CONR^{12}$-phenyl,
(j)(C_{0-6}alkyl)-$CONR^{20}$-V-COR^{11}, and
(k) nothing, when X is O, S, or SO_2),

where W is selected from: a single bond, -O-, -S-, -SO-, -SO_2-, -CO-, -CO_2-, -$CONR^{12}$- and –NR^{12}–, where V is selected from C_{1-6}alkyl or phenyl,

where R^{20} is hydrogen, C_{1-4}alkyl or is joined via a 1-5 carbon tether to one of the carbons of V to form a ring, where the C_{0-6}alkyl is unsubstituted or substituted with 1-5 substituents,

where said substituents are independently selected from: halo, hydroxy, -C_{0-6}alkyl, -O-C_{1-3}alkyl, trifluoromethyl, and -C_{0-2}alkyl-phenyl,

where the phenyl, heterocycle, cycloalkyl, and C_{0-4}alkyl is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from: halo, trifluoromethyl, hydroxy, C_{1-3}alkyl, -O-C_{1-3}alkyl, -C_{0-3}-COR^{11}, -CN, -$NR^{12}R^{12}$, -$CONR^{12}R^{12}$, and -C_{0-3}-heterocycle, or where the phenyl and heterocycle are fused to another heterocycle, which itself is unsubstituted or substituted with 1-2 substituents independently selected from hydroxy, halo, -COR11, and –C1-3alkyl,

and where alkene is unsubstituted or substituted with 1-3 substituents which are independently selected from: halo, trifluoromethyl, C_{1-3}alkyl, phenyl, and heterocycle;

R^8 is selected from:

(a) hydrogen,
(b) nothing when X is either O, S, SO_2 or N or when a double bond joins the carbons to which R^7 and R^{10} are attached,
(c) hydroxy,
(d) C_{1-6}alkyl,
(e) C_{1-6}alkyl-hydroxy,
(f) -O-C_{1-3}alkyl,
(g) -COR^{11},
(h) -$CONR^{12}R^{12}$, and
(i) -CN;

or where R^7 and R^8 are be joined together to form a ring which is selected from:

(a) 1H-indene,
(b) 2,3-dihydro-1H-indene,
(c) 2,3-dihydro-benzofuran,
(d) 1,3-dihydro-isobenzofuran,
(e) 2,3-dihydro-benzothiofuran,
(f) 1,3-dihydro-isobenzothiofuran,
(g) 6*H*-cyclopenta[*d*]isoxazol-3-ol
(h) cyclopentane, and
(i) cyclohexane,

where the ring formed is unsubstituted or substituted with 1-5 substituents independently selected from: halo, trifluoromethyl, hydroxy, C_{1-3}alkyl, -O-C_{1-3}alkyl, -C_{0-3}-COR^{11}, -CN, -$NR^{12}R^{12}$, -$CONR^{12}R^{12}$, and -C_{0-3}-heterocycle,

or where R^7 and R^9 or R^8 and R^{10} are joined together to form a ring which is phenyl or heterocycle, where said ring is unsubstituted or substituted with 1-7 substituents, where said substituents are independently selected from: halo, trifluoromethyl, hydroxy, C_{1-3}alkyl, -O-C_{1-3}alkyl, -COR^{11}, -CN, -$NR^{12}R^{12}$, and -$CONR^{12}R^{12}$;

R^9 and R^{10} are independently selected from:

(a) hydrogen,
(b) hydroxy,
(c) C_{1-6}alkyl,
(d) C_{1-6}alkyl-COR^{11},
(e) C_{1-6}alkyl-hydroxy,
(f) -O-C_{1-3}alkyl,
(g) =O, when R^9 or R^{10} is connected to the ring via a double bond, and

(h) halo;

R^{15} is hydrogen or C_{1-6}alkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, $-CO_2H$, $-CO_2C_{1-6}$alkyl, and $-O-C_{1-3}$alkyl;

R^{16} is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, where alkyl is unsubstituted or substituted with 1-6 substituents where the substituents are selected from: fluoro, C_{1-3}alkoxy, hydroxy, $-COR^{11}$,
(c) fluoro,
(d) $-O-C_{1-3}$alkyl, where alkyl is unsubstituted or substituted with 1-3 fluoro, and
(e) C_{3-6} cycloalkyl,
(f) $-O-C_{3-6}$cycloalkyl,
(g) hydroxy,
(h) $-COR^{11}$,
(i) $-OCOR^{13}$,

or R^{15} and R^{16} are joined together via a C_{2-4}alkyl or a C_{0-2}alkyl-O-C_{1-3}alkyl chain to form a 5-7 membered ring;

R^{17} is selected from:

(a) hydrogen,
(b) C_{1-6}alkyl, where alkyl is unsubstituted or substituted with 1-6 substituents, where said substituents are selected from: fluoro, C_{1-3}alkoxy, hydroxy, $-COR^{11}$,
(c) COR^{11},
(d) hydroxy, and
(e) $-O-C_{1-6}$alkyl, where alkyl is unsubstituted or substituted with 1-6 substituents, where said substituents are selected from: fluoro, C_{1-3}alkoxy, hydroxy, $-COR^{11}$,

or R^{16} and R^{17} are joined together by a C_{1-4}alkyl chain or a C_{0-3}alkyl-O-C_{0-3}alkyl chain to form a 3-6 membered ring;

R^{18} is selected from:

(a) hydrogen, and
(b) C_{1-6}alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,
(c) fluoro,
(d) -O-C_{3-6}cycloalkyl, and
(e) -O-C_{1-3}alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,

or R^{16} and R^{18} are joined together by a C_{2-3}alkyl chain to form a 5-6 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substiuents are independently selected from: halo, hydroxy, -COR^{11}, C_{1-3}alkyl, and C_{1-3}alkoxy;

or R^{16} and R^{18} are joined together by a C_{1-2}alkyl-O-C_{1-2}alkyl chain to form a 6-8 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substiuents are independently selected from: halo, hydroxy, -COR^{11}, C_{1-3}alkyl, and
C_{1-3}alkoxy,

or R^{16} and R^{18} are joined together by a –O-C_{1-2}alkyl-O-chain to form a 6-7 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substiuents are independently selected from: halo, hydroxy, -COR^{11}, C_{1-3}alkyl, and C_{1-3}alkoxy;

R^{19} is selected from:

(a) hydrogen,
(b) phenyl,
(c) C_{1-6}alkyl which is substituted or unsubstituted with 1-6 of the following substituents: -COR^{11}, hydroxy, fluoro, chloro, -O-C_{1-3}alkyl;

or R^2 and R^{19} are joined together to form a heterocycle ring with a linker selected from:

(a) -$CH_2(CR^{28}R^{28})_{1-3}$-,
(b) -CH_2NR^{29}-
(c) -$NR^{29}CR^{28}R^{28}$-,
(d) -CH_2O-,
(e) -CH_2SO_2-,
(f) -CH_2SO-,
(g) -CH_2S-,

(h) -$CR^{28}R^{28}$-,

where R^{28} is selected from selected from:

(a) hydrogen,
(b) hydroxy,
(c) halo,
(d) C_{1-3}alkyl, where the alkyl is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro, and hydroxy,
(e) -$NR^{12}R^{12}$,
(f) -COR^{11},
(g) -$CONR^{12}R^{12}$,
(h) -$NR^{12}COR^{13}$,
(i) -$OCONR^{12}R^{12}$,
(j) -$NR^{12}CONR^{12}R^{12}$,
(k) -heterocycle,
(l) -CN,
(m) -NR^{12}-SO_2-$NR^{12}R^{12}$,
(n) -NR^{12}-SO_2-R^{14},
(o) -SO_2-$NR^{12}R^{12}$, and
(p) =O, where R^{28} is connected to the ring via a double bond and the other R^{28} at the same position is nothing, and

where R^{29} is selected from: hydrogen, C_{1-3}alkyl, where the alkyl is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro, hydroxy, COR^{13}, SO_2R^{14}, and $SO_2NR^{12}R^{12}$;

R^{25} and R^{26} are independently selected from:

(a) =O, where R^{25} and/or R^{26} is oxygen and is connected via a double bond,
(b) hydrogen,
(c) phenyl,
(d) C_{1-6}alkyl which is substituted or unsubstituted with 1-6 of the following substituents: -COR^{11}, hydroxy, fluoro, chloro, -O-C_{1-3}alkyl;

m is selected from 0, 1, or 2;

n is selected from 1 or 2;

the dashed line represents a single or a double bond;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

2. A compound of Claim 1 of formula Ia:



Ia

wherein R^1, R^3, R^5, R^{16}, R^{17}, Y, and Z are defined in Claim 1,

and pharmaceutically acceptable salts and individual diastereomers thereof.

3. A compound of Claim 1 of formula IIa:



IIa

wherein R^1, R^5, R^7, R^8, R^9, R^{10} X and Z are described in Claim 1, and pharmaceutically acceptable salts and individual diastereomers thereof.

4. A compound of Claim 1 of formula IIb:



IIb

wherein R^1, R^3, R^5, R^7, R^8, R^9, R^{10}, X, and Z are defined in Claim 1,

and pharmaceutically acceptable salts and individual diastereomers thereof.

5. A compound of Claim 1 of formula IIc:



IIc

wherein R^1, R^3, R^5, R^{10}, and Z are described in Claim 1, and
R^{23} and R^{24} are independently selected from:

(a) hydrogen,
(b) halo,
(c) trifluoromethyl,
(d) hydroxy,
(e) C_{1-3}alkyl,
(f) -O-C_{1-3}alkyl,
(g) -C_{0-3}-CO_2H,
(h) -C_{0-3}-CO_2C_{1-3}alkyl,
(i) -CN, and
(j) -C_{0-3}-heterocycle,

or where the R23 and R24 are joined together to form a heterocycle which is fused to the phenyl ring, and which itself is unsubstituted or substituted with 1-2 substituents independently selected from hydroxy, halo, -COR11, and –C_{1-3}alkyl;

and pharmaceutically acceptable salts and individual diastereomers thereof.

6. A compound of Claim 1 of formula IId:



IId

wherein R^1, R^3, R^5 ,R^9, R^{23}, R^{24}, and Z are defined in Claim 1 and the dashed line represents a single or a double bond,

and pharmaceutically acceptable salts and individual diastereomers thereof.

7. A compound of Claim 1 of formula IIe:



IIe

wherein R^1, R^3, R^5, R^{10}, R^{23}, and R^{24} are described in Claim 1, and pharmaceutically acceptable salts and individual diastereomers thereof.

8. A compound of Claim 1 of formula IIf:



IIf

wherein R^1, R^3, R^5 ,R^9, R^{23}, and R^{24} are defined in Claim 1,

and pharmaceutically acceptable salts and individual diastereomers thereof.

9. A compound of Claim 8 wherein R^1 is selected from: hydrogen, phenyl, heterocycle, -C_{1-6}alkyl, -C_{0-6}alkyl-O-C_{1-6}alkyl, and -(C_{0-6}alkyl)-(C_{3-7}cycloalkyl)-(C_{0-6}alkyl),

where said alkyl, phenyl, heterocycle, and cycloalkyl are unsubstituted or substituted with 1-7 substituents, where said substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl,
(f) C_{1-3}alkyl,
(g) -O-C_{1-3}alkyl,
(h) -COR^{11},
(i) -CN,
(j) -$NR^{12}R^{12}$, and
(k) -$CONR^{12}R^{12}$.

10. A compound of Claim 9 wherein R^1 is selected from:
(1) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 substituents where said substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl, and
(e) -COR^{11},
(2) -C_{0-6}alkyl-O-C_{1-6}alkyl-, which is unsubstituted or substituted with 1-6 substituents where said substituents are independently selected from:
(a) halo,
(b) trifluoromethyl, and
(c) -COR^{11},
(3) -(C_{3-5}cycloalkyl)-(C_{0-6}alkyl), which is unsubstituted or substituted with 1-7 substituents where said substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl, and
(e) -COR^{11},
(4) phenyl or heterocycle which is unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl,
(d) trifluoromethyl, and
(e) -COR^{11}.

11. A compound of Claim 10 wherein R^1 is selected from:
(a) hydrogen,
(b) C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro and hydroxy
(c) phenyl, and
(d) pyridyl.

12. A compound of Claim 6 wherein Z is C and R^3 is selected from:
(a) hydrogen
(b) halo
(c) hydroxy
(d) C_{1-3}alkyl, where the alkyl is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro, and hydroxy,
(e) $-COR^{11}$,
(f) $-CONR^{12}R^{12}$,
(g) -heterocycle,
(h) $-NR^{12}-SO_2-NR^{12}R^{12}$,
(i) $-NR^{12}-SO_2-R^{14}$,
(j) $-SO_2-NR^{12}R^{12}$,
(k) -nitro, and
(l) -NR12R12.

13. A compound of Claim 12 wherein Z is C, R^3 is selected from:
(a) fluoro,
(b) trifluoromethyl,
(c) hydrogen.

14. A compound of Claim 8 wherein R^5 is selected from:
(a) C_{1-6}alkyl substituted with 1-6 fluoro,
(b) $-O-C_{1-6}$alkyl substituted with 1-6 fluoro,
(c) chloro,
(d) bromo, and
(e) phenyl.

15. A compound of Claim 4 wherein R^7 is phenyl, heterocycle, C_{3-7}cycloalkyl, C_{1-6}alkyl, $-COR^{11}$, and $-CONH-V-COR^{11}$, where V is selected from C_{1-6}alkyl or phenyl, and

where the phenyl, heterocycle, C_{3-7}cycloalkyl, and C_{1-6}alkyl is unsubstituted or substituted with 1-5 substituents, where said substituents are independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -COR^{11},
(g) -CN,
(h) -heterocycle, and
(i) -$CONR^{12}R^{12}$.

16. A compound of Claim 15 wherein, when X is not O, R^7 is phenyl, heterocycle, C_{1-4}alkyl, –COR^{11} or -CONH-V-COR^{11};
V is selected from C_{1-6}alkyl or phenyl; and
the phenyl, heterocycle, and C_{1-4}alkyl is unsubstituted or substituted with 1-3 substituents, where said substituents are independently selected from:

(a) halo,
(b) hydroxy,
(c) C_{1-3}alkyl,
(d) -O-C_{1-3}alkyl,
(e) -COR^{11},and
(f) -heterocycle.

17. A compound of Claim 7 wherein R^{10} is selected from:

(a) hydrogen,
(b) hydroxy,
(c) -CH_3;
(d) -O-CH_3, and
(e) =O (where R^9 is joined to the ring via a double bond).

18. A compound of Claim 2 wherein R^{16} is selected from:

(a) hydrogen,
(b) C_{1-3}alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(c) -O-C_{1-3}alkyl,
(d) fluoro, and
(e) hydroxy.

19. A compound of Claim 18 wherein R^{16} is selected from:
(a) hydrogen,
(d) trifluoromethyl,
(c) methyl,
(d) methoxy,
(e) ethoxy,
(f) ethyl,
(g) fluoro, and
(h) hydroxy.

20. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

21. A method for modulation of chemokine receptor activity in a mammal which comprises the administration of an effective amount of a compound of Claim 1.

22. A method for treating, ameliorating, controlling or reducing the risk of an inflammatory and immunoregulatory disorder or disease which comprises the administration to a patient of an effective amount of a compound of Claim 1.

23. A method for treating, ameliorating, controlling or reducing the risk of rheumatoid arthritis which comprises the administration to a patient of an effective amount of a compound of Claim 1.